Moreover, the prognoses of patients with different CRLF2 expression levels were validated using the B-ALL patient cohort from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) public database. The gene discussed is CRLF2; the disease is acute lymphoblastic leukemia.